journal
MENU ▼
Read by QxMD icon Read
search

Cancer Management and Research

journal
https://www.readbyqxmd.com/read/28496364/oligodendrogliomas-in-pediatric-and-adult-patients-an-outcome-based-study-from-the-surveillance-epidemiology-and-end-result-database
#1
Christine Sm Lau, Krishnaraj Mahendraraj, Ronald S Chamberlain
INTRODUCTION: Oligodendrogliomas (OGs) account for <20% of all intracranial tumors and 25% of gliomas. Despite improvements in imaging techniques allowing for earlier diagnosis, OG is rare among the pediatric population. This study examines a large cohort of OG patients in an effort to define the demographic, clinical, and pathologic factors associated with clinical and survival outcomes. METHODS: Data on 7,001 OG patients were abstracted from the Surveillance, Epidemiology, and End Result (SEER) database (1973-2013)...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28490902/patient-and-physician-preferences-for-anticancer-drugs-for-the-treatment-of-metastatic-colorectal-cancer-a-discrete-choice-experiment
#2
Juan Marcos González, Sarika Ogale, Robert Morlock, Joshua Posner, Brett Hauber, Nicolas Sommer, Axel Grothey
OBJECTIVE: Many publications describe preferences for colorectal cancer (CRC) screening; however, few studies elicited preferences for anticancer-drug treatment for metastatic CRC (mCRC). This study was designed to elicit preferences and risk tolerance among patients and oncologists in the USA for anticancer drugs to treat mCRC. MATERIALS AND METHODS: Patients aged 18 years or older with a self-reported diagnosis of mCRC and board-certified (or equivalent) oncologists who had treated patients with mCRC were recruited by two survey research companies from existing online patient panels in the USA...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28479860/rituximab-in-the-treatment-of-follicular-lymphoma-the-future-of-biosimilars-in-the-evolving-therapeutic-landscape
#3
REVIEW
Janakiraman Subramanian, Jamie Cavenagh, Bhardwaj Desai, Ira Jacobs
Follicular lymphoma (FL) is the second most common type of non-Hodgkin's lymphoma. FL is an incurable disease with treatment options ranging from a "watch-and-wait" approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development. Despite the prospect of new agents on the horizon, it is widely accepted that rituximab will remain as the cornerstone of therapy because of its established long-term efficacy...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28461766/comparative-effectiveness-and-resource-utilization-of-nab-paclitaxel-plus-gemcitabine-vs-folfirinox-or-gemcitabine-for-the-first-line-treatment-of-metastatic-pancreatic-adenocarcinoma-in-a-us-community-setting
#4
Fadi Braiteh, Manish B Patel, Monika Parisi, Quanhong Ni, Siyeon Park, Claudio Faria
INTRODUCTION: Despite a clinically relevant, statistically significant survival benefit with nab-paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer (mPC), little is known regarding their real-world effectiveness. We analyzed patients with mPC using a nationally representative electronic medical records database to address this unmet need. METHODS: This retrospective analysis of the Navigating Cancer database compared outcomes among patients who received first-line nab-paclitaxel plus gemcitabine, FOLFIRINOX, or gemcitabine for mPC...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28442933/drainage-of-malignant-ascites-patient-selection-and-perspectives
#5
REVIEW
Maciej Stukan
Malignant ascites (MA) is a sign of advanced cancer and poor prognosis. MA can result in impairment in quality of life (QOL) and significant symptoms. As a supportive treatment, ascites can be drained by paracentesis (PC), percutaneously implanted catheters (tunneled, untunneled, central venous catheters), or peritoneal ports, or peritoneovenous shunts. The aim of this study was to evaluate the effectiveness, safety, and patient-reported outcomes (PRO) of different drainage methods for the management of MA...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28435325/the-clinical-development-of-obinutuzumab-for-the-treatment-of-follicular-lymphoma
#6
REVIEW
Barbara Ma, Chaitra Ujjani
Impressive progress has been made in recent decades for advanced-stage follicular lymphoma with the availability of anti-CD20 monoclonal antibodies, initially rituximab and more recently obinutuzumab. Obinutuzumab is a unique, third-generation, fully humanized glycoengineered IgG1 type II anti-CD20 monoclonal antibody. It has been shown to have increased antitumor activity compared to rituximab in preclinical studies, including whole-blood B-cell depletion assays, xenograft models, and primate models. This has spurred on the development of obinutuzumab through Phase I/II trials as monotherapy and in combination with chemotherapeutic agents and other targeted therapies...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28435324/symptomatic-central-nervous-system-involvement-in-adult-patients-with-acute-myeloid-leukemia
#7
Nael Alakel, Friedrich Stölzel, Brigitte Mohr, Michael Kramer, Uta Oelschlägel, Christoph Röllig, Martin Bornhäuser, Gerhard Ehninger, Markus Schaich
INTRODUCTION: Acute myeloid leukemia (AML) rarely involves the central nervous system (CNS). Little is known about the clinical course in adult AML patients since most studies examined pediatric patients. Therefore, this study analyzed the data of patients treated in three prospective trials of the "Study Alliance Leukemia" (SAL) study group for CNS involvement. METHODS: In all, 3,261 AML patients included in the prospective AML96, AML2003, and AML60+ trials of the SAL study group were analyzed...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28356771/nab-paclitaxel-for-the-treatment-of-pancreatic-cancer
#8
REVIEW
George Kim
BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-P) plus gemcitabine (Gem) became a standard treatment option for metastatic pancreatic cancer (MPC) following positive results from a global phase III trial (MPACT). A large number of studies have now published results on the use of nab-P/Gem to treat advanced and early-stage disease, warranting a comprehensive review. The main goal of this systematic review is to summarize the efficacy and safety data of nab-P/Gem for the treatment of pancreatic cancer (PC)...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28331368/new-developments-in-the-management-of-waldenstr%C3%A3-m-macroglobulinemia
#9
REVIEW
Jithma P Abeykoon, Uday Yanamandra, Prashant Kapoor
Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral Bruton's tyrosine kinase inhibitor that has recently been approved for WM in the United States, Europe, and Canada...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28293120/glucocorticoid-receptor-expression-in-20-solid-tumor-types-using-immunohistochemistry-assay
#10
Thaddeus S Block, Tiffany I Murphy, Pamela N Munster, Dat P Nguyen, Frank J Lynch
BACKGROUND: Glucocorticoid receptor (GR) activity plays a role in many aspects of human physiology and may play a crucial role in chemotherapy resistance in a wide variety of solid tumors. A novel immunohistochemistry (IHC) based assay has been previously developed and validated in order to assess GR immunoreactivity in triple-negative breast cancer. The current study investigates the standardized use of this validated assay to assess GR expression in a broad range of solid tumor malignancies...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28280389/update-on-the-optimal-use-of-bortezomib-in-the-treatment-of-multiple-myeloma
#11
REVIEW
Meera Mohan, Aasiya Matin, Faith E Davies
The proteasome inhibitor (PI) "bortezomib" has now been in routine clinical practice for over a decade. It is now considered an important backbone therapy for all stages of the disease, and data continue to grow to support its use in newly diagnosed patients, relapsed and relapsed/refractory disease, maintenance therapy, high risk, and renal failure. Much has been learnt about the most clinically effective way of delivering therapy, with patients often benefiting more from a triplet bortezomib combination compared to a doublet combination...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28260945/differential-pharmacology-and-clinical-utility-of-rolapitant-in-chemotherapy-induced-nausea-and-vomiting
#12
REVIEW
Bernardo Leon Rapoport
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is largely managed with 5-hydroxytryptamine 3 receptor antagonists. The delayed phase, a 5-day at-risk period during which patients are not often in direct contact with their health care provider, remains a significant unmet medical need. Neurokinin-1 (NK-1) receptor antagonists have demonstrated protection against acute and delayed CINV in patients treated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy when used in combination with a 5-hydroxytryptamine 3 receptor antagonist and dexamethasone...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28228661/feasibility-of-an-exercise-intervention-for-fatigued-breast-cancer-patients-at-a-community-based-cardiac-rehabilitation-program
#13
Stefanie De Jesus, Lyndsay Fitzgeorge, Karen Unsworth, David Massel, Neville Suskin, Harry Prapavessis, Michael Sanatani
PURPOSE: Exercise is beneficial to quality of life after cancer treatment, yet few cancer survivors meet exercise guidelines. Our study sought to determine the feasibility of an oncology rehabilitation exercise program embedded within a cardiac rehabilitation program. METHODS: Patients who rated their fatigue >4/10 after completion of adjuvant chemotherapy for breast cancer were screened for eligibility and the outcomes were assessed (Piper Fatigue Scale, Functional Assessment of Cancer Therapy-Breast [FACT-B], Edmonton Symptom Assessment System, body composition, stress test, and physical activity measurement [accelerometer])...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28223846/prospect-of-the-use-of-checkpoint-inhibitors-in-hepatocellular-cancer-treatments
#14
REVIEW
Ali Raufi, Maria Tria Tirona
Hepatocellular cancer (HCC) is a very fatal disease due to limited therapeutic options as well as due to its association with underlying chronic liver disease in the majority of cases. The immune evasion in HCC signifies a major barrier to the delivery of effective immunotherapy. Sorafenib is the only Food and Drug Administration-approved drug available with an overall response rate of 2%-3% and overall survival of 2.8 months. Chemotherapy has not been used routinely because of the relative refractoriness of advanced HCC...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28203106/antioxidant-activity-of-ginger-extract-as-a-daily-supplement-in-cancer-patients-receiving-adjuvant-chemotherapy-a-pilot-study
#15
Kwanjit Danwilai, Jitprapa Konmun, Bung-Orn Sripanidkulchai, Suphat Subongkot
PURPOSE: The aim of this study was to examine the antioxidant activity of ginger extract oral supplement in newly diagnosed cancer patients receiving adjuvant chemotherapy compared to placebo. PATIENTS AND METHODS: Newly diagnosed cancer patients receiving moderate-to-high emetogenic potential adjuvant chemotherapy were randomized to receive either a ginger extract (standardized 6-gingerol 20 mg/day) or a placebo 3 days prior to chemotherapy, which they continued daily...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28203105/association-of-fatigue-and-depression-with-circulating-levels-of-proinflammatory-cytokines-and-epidermal-growth-factor-receptor-ligands-a-correlative-study-of-a-placebo-controlled-fatigue-trial
#16
Tyvin Rich, Fengmin Zhao, Ricardo A Cruciani, David Cella, Judith Manola, Michael J Fisch
CONTEXT: The biology of fatigue and depression in cancer patients is poorly understood. Hypotheses regarding cytokines and growth factors related to sickness behavior and disruption of circadian signaling have been proposed. OBJECTIVES: We prospectively examined proinflammatory cytokines (e.g., sickness behavior model) and epidermal growth factor receptor (EGFR) ligands (e.g., circadian disruption model) in the serum of cancer patients enrolled in a clinical trial testing levocarnitine for fatigue...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/27877066/implantation-of-permanent-pleural-catheter-for-palliation-of-malignant-pleural-effusion
#17
Michelle Meier, Marie Riis Mortensen, Lene Unmack Larsen
PURPOSE: Malignant pleural effusion (MPE) is a disabling condition caused in most instances by far-advanced cancer. The treatment is palliative and should ideally be minimally invasive. The aim of this retrospective study was to evaluate the effectiveness of implantation of a permanent PleurX catheter in the treatment of recurrent MPE in patients with terminal cancer disease. PATIENTS AND METHODS: Eighteen consecutive patients with terminal cancer and MPE, who had a permanent PleurX catheter implanted in the period from February 2014 to August 2015, were retrospectively evaluated...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27799819/treatment-challenges-for-community-oncologists-treating-postmenopausal-women-with-endocrine-resistant-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer
#18
https://www.readbyqxmd.com/read/27695363/atypical-teratoid-rhabdoid-tumors-challenges-and-search-for-solutions
#19
REVIEW
Ahitagni Biswas, Lakhan Kashyap, Aanchal Kakkar, Chitra Sarkar, Pramod Kumar Julka
Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal central nervous system tumor commonly affecting children <3 years of age. It roughly constitutes 1%-2% of all pediatric central nervous system tumors. Recent data show that it is the most common malignant central nervous system tumor in children <6 months of age. Management of this aggressive tumor is associated with a myriad of diagnostic and therapeutic challenges. On the basis of radiology and histopathology alone, distinction of AT/RT from medulloblastoma or primitive neuroectodermal tumor is difficult, and hence this tumor has been commonly misdiagnosed as primitive neuroectodermal tumor for decades...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27578998/role-of-tolvaptan-in-the-management-of-hyponatremia-in-patients-with-lung-and-other-cancers-current-data-and-future-perspectives
#20
REVIEW
Bijin Thajudeen, Abdulla K Salahudeen
Hyponatremia is the most frequently observed electrolyte abnormality in clinical practice, and its frequency is almost double in hospitalized cancer patients. As a subset of cancer, hyponatremia is quite common in lung cancer patients, and it is often coupled with the diagnosis of syndrome of inappropriate antidiuretic hormone secretion. The presence of hyponatremia is consequential in that its presence adversely affects cancer patients' prognosis and outcomes. Limited data suggest that correcting hyponatremia in lung cancer patients can increase response to anticancer treatment, may help reduce length of hospital stay and cost, and reduce morbidity and mortality...
2016: Cancer Management and Research
journal
journal
42502
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"